PULM Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States...

Stats
Šios dienos apimtis	6 759.00
Vidutinė apimtis	15 388.00
Rinkos kapitalizacija	7.45M
EPS	$-0.570 ( 2024-04-04 )
Kita pelno data	( $-1.040 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.530
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-01-26	Siegert Michelle	Buy	9 900	Stock Option (Right to Buy)
2023-01-26	Wasilewski Margaret	Buy	11 400	Stock Option (Right to Buy)
2023-01-26	Raad Teofilo David	Buy	34 900	Stock Option (Right to Buy)
2023-01-26	Bazemore Todd	Buy	1 700	Stock Option (Right to Buy)
2023-01-26	Higgins Michael J	Buy	2 436	Stock Option (Right to Buy)

INSIDER POWER
100.00
Last 94 transactions
Buy: 13 676 591 \| Sell: 104 308

Pulmatrix Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Pulmatrix Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$7.30M
Bruto pelnas:	$5.82M (79.79 %)
EPS:	$-3.87

FY	2023
Pajamos:	$7.30M
Bruto pelnas:	$5.82M (79.79 %)
EPS:	$-3.87

FY	2022
Pajamos:	$6.07M
Bruto pelnas:	$4.53M (74.55 %)
EPS:	$-5.43

FY	2021
Pajamos:	$5 169.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-0.00745

Financial Reports:

No articles found.

Pulmatrix Inc

Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma, and in patients with cystic fibrosis; PUR1800, a narrow spectrum kinase inhibitor that is in Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a collaboration and license agreement with Sensory Cloud, Inc. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.